Takeda Pharmaceuticals U.S.A. v. Hikma Americas Inc., No. 15-1139 (Fed. Cir. May 6, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) ap- peals the order of the United States District Court for the District of Delaware denying its motion for preliminary injunction. Takeda sought to enjoin West-Ward Pharma- ceutical Corporation, Hikma Americas Inc., and Hikma Pharmaceuticals PLC (collectively “Hikma”) from continu- ing its launch of Mitigare, a colchicine product for prophy- lactic treatment of gout, and from launching an authorized generic version of Mitigare. We affirm. TAKEDA PHARMACEUTICALS U.S.A. v. HIKMA AMERICAS INC.